Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly versus 3-weekly cabazitaxel in metastatic castration-resistant prostate cancer
2011-004178-27Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Dec 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Karolinska University Hospital. Started Dec 2011; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-004178-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004178-27.